As a prudent investor have you not considered the possibility that MHRA has asked NWBIO to provide patient-level data for the ECAs, a request with which NWBIO is unable to comply? As a prudent investor, have you not considered that this is, in fact, the most likely scenario? As a prudent investor, are you not at least somewhat concerned that company management has elected to keep shareholders in the dark about pretty much darn near everything since, oh, about 2015? As you weigh your investment, would you not consider this a very bad indicator?
And speaking of bad indicators, since this trial's inception over 15 years ago, the company published its intent to complete the trial and submit results to the FDA. That sequence of events was discussed on this message board for many years and was assumed to be a given. It was accepted that that is what would happen, and the company even stated this very clearly itself. And yet, in the end they did not submit results to the FDA, the regulator of the world's largest and most lucrative health care market. They instead submitted results to the MHRA, the regulator of the relatively tiny UK health care market. As a prudent investor, would you not consider this decision a very, very bad indicator?
As a prudent investor, why are you still holding this $0.25 stock that, at this point, has zero chance of generating any significant revenue for many years down the road even if by some miracle it does obtain MHRA approval?
AI
Market Data 
Markets 
